19/09/2025, Friday05:46
flag
Yeni Şafak

EDITION   :

TRTRENENARARFRFRRURUURUR

South Korea backs remdesivir for COVID-19, urges caution with dexamethasone

Şeyda Aydın
11:09, 26/06/2020, Friday
REUTERS
South Korea backs remdesivir for COVID-19, urges caution with dexamethasone

South Korea has added Gilead's anti-viral drug remdesivir to its coronavirus treatment guidelines in its first revision of recommendations since the outbreak began and urged caution in the use of the steroid therapy dexamethasone.

Reklam yükleniyor...

Reklam yükleniyor...

South Korea, widely praised around the world for its handling of the pandemic without a full lockdown, has reported 12,602 coronavirus cases as of Thursday midnight, with 282 deaths.

Remdesivir is designed to hinder certain viruses, including the new coronavirus, from making copies of themselves and potentially overwhelming the body's immune system. The drug previously failed trials as an Ebola treatment.

South Korea's updated guidelines come after a study showed that the cheap and widely used dexamethasone reduced deaths in very sick COVID-19 patients. They advised doctors to take caution until a full study is published.

"It seems appropriate to administer (dexamethasone), limited to severe cases with acute respiratory syndrome, as the doctor monitors the patient's condition," Kim Young-ok, director general of pharmaceutical safety bureau at the Ministry of Food and Drug Safety, told a briefing on Friday.

There was enough domestic supply of the dexamethasone, widely used since the 1960s, with the production of approximately 43 million tablets and 60 million injection ampoules a year, said Kim.

Doctors in Europe will soon be able to treat patients with the drug after the healthcare regulator's endorsement put it on track to become the first therapy for the disease on the continent.

"An excessive use of dexamethasone can trigger different side effects as it tamps down the immune system along with inflammation, possibly leading to even cataract or glaucoma," said Dr. Song Dae-sub, professor of pharmacy at Korea University.

Korean health authorities also advised the dropping of hydroxychloroquine after a study found the decades-old malaria drug, which U.S. President Donald Trump touted a possible treatment, did not provide any benefit.

There are currently no approved vaccines or treatments for the coronavirus, which has killed more than 488,467 people globally, but about a dozen vaccines from more than 100 candidates globally are being tested on humans.

Reklam yükleniyor...

Reklam yükleniyor...

Comments
user

Comments you share on our site are a valuable resource for other users. Please be respectful of different opinions and other users. Avoid using rude, aggressive, derogatory, or discriminatory language.

Turkey's Accumulation. International Media Group.

Welcome to the news source that sets Turkey's agenda! With its impartial, dynamic, and in-depth journalism, Yeni Şafak offers its readers an experience beyond current events. Get instant updates on what's happening in Turkey and worldwide, with news spanning a wide range from politics and economy to culture, arts, and sports. Access the most accurate information anytime, anywhere with its digital platforms; keep up with the agenda with Yeni Şafak!

Follow us on social media.
Download Mobile Apps

Carry the agenda in your pocket! With Yeni Şafak's mobile apps, get instant access to the latest news. A wide range of content, from politics to economy, sports to culture and arts, is at your fingertips! Easily download it on your iOS, Android, and Huawei devices to quickly access the most accurate information anytime, anywhere. Download now, don't miss out on developments around the world!

Categories
Albayrak Media

Maltepe Mah. Fetih Cad. No:6 34010 Zeytinburnu/İstanbul, Türkiyeiletisim@yenisafak.com+90 212 467 6515

LEGAL DISCLAIMER

The BIST name and logo are protected under a 'Protection Trademark Certificate' and cannot be used, quoted, or modified without permission. All information disclosed under the BIST name is fully copyrighted by BIST and may not be republished. Market data is provided by iDealdata Financial Technologies Inc. BIST stock data is delayed by 15 minutes.

© Net Medya, All right reserved. 2025